Unknowns of drug company payment disclosure : why the UK needs payment transparency legislation
(2025) In BMJ Evidence-Based Medicine- Abstract
- New government legislation is necessary to ensure full transparency of industry payments in the UK’s healthcare. A first step should involve challenging the industry- driven discourse that allows company payment disclosures to be inconsequential for managing conflicts of interest.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/eb7e54db-7b66-47d6-8f85-1e106a1ace26
- author
- Ozieranski, Piotr ; Rickard, Emily and Mulinari, Shai LU
- organization
- publishing date
- 2025-01-07
- type
- Contribution to journal
- publication status
- epub
- subject
- in
- BMJ Evidence-Based Medicine
- publisher
- BMJ Publishing Group
- external identifiers
-
- pmid:39773928
- scopus:85214529322
- ISSN
- 2515-446X
- DOI
- 10.1136/bmjebm-2024-113101
- project
- Following the money: cross-national study of pharmaceutical industry payments to medical associations and patient organisations
- language
- English
- LU publication?
- yes
- id
- eb7e54db-7b66-47d6-8f85-1e106a1ace26
- date added to LUP
- 2025-01-09 16:51:19
- date last changed
- 2025-07-14 14:39:24
@article{eb7e54db-7b66-47d6-8f85-1e106a1ace26, abstract = {{New government legislation is necessary to ensure full transparency of industry payments in the UK’s healthcare. A first step should involve challenging the industry- driven discourse that allows company payment disclosures to be inconsequential for managing conflicts of interest.}}, author = {{Ozieranski, Piotr and Rickard, Emily and Mulinari, Shai}}, issn = {{2515-446X}}, language = {{eng}}, month = {{01}}, publisher = {{BMJ Publishing Group}}, series = {{BMJ Evidence-Based Medicine}}, title = {{Unknowns of drug company payment disclosure : why the UK needs payment transparency legislation}}, url = {{http://dx.doi.org/10.1136/bmjebm-2024-113101}}, doi = {{10.1136/bmjebm-2024-113101}}, year = {{2025}}, }